NCT00481962View on ClinicalTrials.gov

Health Economic Assessment of Tygacil® in the Treatment of Secondary Peritonitis in Intensive Care Units (ICUs)

CompletedOBSERVATIONAL

Enrollment

180

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions

Peritonitis

Interventions

DRUG

Tygacil

Initial dose of 100mg followed by 50mg every 12 hours for 5 to 14 days

Trial Locations (1)

Unknown

Multiple Cities

All Listed Sponsors

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00481962 - Health Economic Assessment of Tygacil® in the Treatment of Secondary Peritonitis in Intensive Care Units (ICUs) | Biotech Hunter | Biotech Hunter